样式: 排序: IF: - GO 导出 标记为已读
-
A secondary daily persistent headache from onset with underlying nutcracker physiology and spinal epidural venous congestion: case series with lumbar vein embolization as a therapeutic approach. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-11-22 Todd D Rozen,Zlatko Devcic,Andrew R Lewis,Sukhwinder J S Sandhu,Young Erben,Beau B Toskich
The authors have published on a unique subset of patients whose headaches worsened in the Trendelenburg position and who on time-resolved MR angiography demonstrated left renal vein compression (nutcracker physiology) with retrograde left second lumbar vein (L2LV) flow and regional spinal epidural venous plexus (EVP) congestion. We hypothesized that the spinal EVP congestion subsequently causes a secondary
-
Multimodal imaging-based diagnostic approach for MRI-negative posterior cortex epilepsy. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-11-18 Jiajie Mo,Wenyu Dong,Lin Sang,Zhong Zheng,Qiang Guo,Xiuming Zhou,Wenjing Zhou,Haixiang Wang,Xianghong Meng,Yi Yao,Fengpeng Wang,Wenhan Hu,Kai Zhang,Xiaoqiu Shao
Background Posterior cortex epilepsy (PCE) primarily comprises seizures originating from the occipital, parietal, and/or posterior edge of the temporal lobe. Electroclinical dissociation and subtle imaging representation render the diagnosis of PCE challenging. Improved methods for accurately identifying patients with PCE are necessary. Objectives To develop a novel voxel-based image postprocessing
-
The vascular locked-in and locked-in-plus syndrome: A retrospective case series. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-11-16 Laura Schnetzer,Jürgen Steinbacher,Gerhard Bauer,Alexander Baden Kunz,Jürgen Bergmann,Martin Kronbichler,Eugen Trinka,Mark McCoy
The locked-in syndrome (LiS) is defined as the loss of most voluntary muscle movements with preserved cognitive abilities due to a ventral pontine lesion. However, some patients may also have severe impairment of consciousness [locked-in plus syndrome (LiPS)]. Here we aimed to explore structural differences between LiS and LiPS patients of vascular aetiology, focusing on lesion patterns and locations
-
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-11-10 Kimberley Allen-Philbey,Stefania De Trane,Amy MacDougall,Ashok Adams,Lucia Bianchi,Thomas Campion,Gavin Giovannoni,Sharmilee Gnanapavan,David W Holden,Monica Marta,Joela Mathews,Benjamin P Turner,David Baker,Klaus Schmierer
Background Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges in others. The characteristics of pwMS developing re-emerging disease activity remain incompletely understood. Objectives To explore whether clinical and/or paraclinical baseline characteristics
-
Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-11-09 Jan Kassubek,Fabrizio Stocchi,Ernest Balaguer Martinez,Rajesh Pahwa,William Ondo,Yi Zhang,Alyssa Bowling,Eric Pappert,Stuart Isaacson,Stacy Wu,
Background Dose optimization of sublingual apomorphine (SL-APO), a dopamine agonist for the treatment of OFF episodes in patients with Parkinson's disease (PD), has been performed under clinical supervision in clinical trials. SL-APO may be a candidate for home dosing optimization which would be less burdensome for patients. Objectives To evaluate the feasibility and safety of home optimization of
-
Perspective: Industry-patient relationships for the promotion of pharmaceutical agents. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-10-31 Meredith A Bryarly,Michael A Rubin,Olaf Stuve
-
Treatment of acute ischemic stroke in patients with active malignancy: insight from a comprehensive stroke center. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-10-31 Woon Hyung Chae,Annika Vössing,Yan Li,Cornelius Deuschl,Lennart Steffen Milles,Jordi Kühne Escolà,Anika Hüsing,Marvin Darkwah Oppong,Philipp Dammann,Martin Glas,Michael Forsting,Christoph Kleinschnitz,Martin Köhrmann,Benedikt Frank
Background Despite the high incidence of acute ischemic stroke (AIS) in cancer patients, there is still no consensus about the safety of recanalization therapies in this cohort. Objectives In this observational study, our aim was to investigate the bleeding risk after acute recanalization therapy in AIS patients with active malignancy. Methods and Study Design We retrospectively analyzed observational
-
Optimizing treatment persistence in epilepsy: a comparative analysis of combined antiseizure medications with different mechanisms of action. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-10-31 Chun-Wei Chang,Wei-En Johnny Tseng,Wey-Ran Lin,Po-Chuan Ko,Chun-Jing Liu,Siew-Na Lim
Background Combination therapy with antiseizure medications (ASMs) is a rational strategy if monotherapy cannot effectively control seizures, thereby aiming to improve tolerance and treatment persistence. Objectives To compare the efficacy of different ASM combinations among patients. Design Patients with epilepsy on monotherapy who had a second ASM added as concomitant two-drug therapy from January
-
Long-term efficacy and adverse effects of cannabidiol in adjuvant treatment of drug-resistant epilepsy: a systematic review and meta-analysis. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-10-30 Shengyi Liu,Zihua He,Jinmei Li
Background Epilepsy is one of the most common chronic brain diseases. Almost one-third of patients have drug-resistant epilepsy (DRE). Cannabidiol is being considered as a potential novel drug for treating DRE. Objectives To investigate long-term efficacy and safety of cannabidiol in treatment of DRE and the differences in cannabidiol treatment among patients with different characteristics. Design
-
Corneal immune cells as a biomarker of inflammation in multiple sclerosis: a longitudinal study. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-10-29 Ioannis N Petropoulos,Karen John,Fatima Al-Shibani,Georgios Ponirakis,Adnan Khan,Hoda Gad,Ziyad R Mahfoud,Heba Altarawneh,Muhammad Hassan Rehman,Dhabia Al-Merekhi,Pooja George,Faiza Ibrahim,Reny Francis,Beatriz Canibano,Dirk Deleu,Ahmed El-Sotouhy,Surjith Vattoth,Mark Stettner,Ahmed Own,Ashfaq Shuaib,Naveed Akhtar,Saadat Kamran,Rayaz A Malik
Background Corneal immune cells (ICs) are antigen-presenting cells that are known to increase ocular and systemic inflammatory conditions. Objective We aimed to assess longitudinal changes in corneal IC in patients with multiple sclerosis (MS) and relation to disability and ongoing treatment. Design Prospective observational study conducted between September 2016 and February 2020. Methods Patients
-
Structural connections of the centromedian nucleus of thalamus and their relevance for neuromodulation in generalized drug-resistant epilepsy: insight from a tractography study. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-10-10 Luigi G Remore,Ziad Rifi,Hiroki Nariai,Dawn S Eliashiv,Aria Fallah,Benjamin D Edmonds,Joyce H Matsumoto,Noriko Salamon,Meskerem Tolossa,Wexin Wei,Marco Locatelli,Evangelia C Tsolaki,Ausaf A Bari
Background Epilepsy is a widespread neurologic disorder and almost one-third of patients suffer from drug-resistant epilepsy (DRE). Neuromodulation targeting the centromediannucleus of the thalamus (CM) has been showing promising results for patients with generalized DRE who are not surgical candidates. Recently, the effect of CM- deep brain stimulation (DBS) in DRE patients was investigated in the
-
Epileptic seizures at multiple sclerosis onset and their role in disease progression. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-10-06 Matthias Grothe,David Ellenberger,Paulus S Rommer,Alexander Stahmann,Uwe K Zettl
Background Epileptic seizures can occur throughout the course of multiple sclerosis (MS) and are associated with increasing disability progression over time. However, there are no data on whether epileptic seizures at the onset of MS also lead to increasing disability. Objective To examine disease progression over time for MS patients with epileptic seizures at onset. Methods We analyzed the data of
-
Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-10-06 Marco Puthenparampil,Marta Gaggiola,Alessandro Miscioscia,Valentina Annamaria Mauceri,Federica De Napoli,Giovanni Zanotelli,Mariagiulia Anglani,Margherita Nosadini,Stefano Sartori,Paola Perini,Francesca Rinaldi,Paolo Gallo
Background Paediatric-onset multiple sclerosis (POMS) therapeutic approach derives from of adult-onset multiple sclerosis (AOMS) tailored algorithms. Objectives To evaluate in a common clinical scenario the efficacy and safety of alemtuzumab (ALZ) in POMS and AOMS. Methods All patients switching from natalizumab (NTZ) to ALZ for safety concerns (high anti-John Cunningham Virus Antibody Index value
-
Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-09-28 Antonios Bayas,Achim Berthele,Norbert Blank,Peter Dreger,Simon Faissner,Manuel A Friese,Lisa-Ann Gerdes,Oliver Martin Grauer,Vivien Häussler,Christoph Heesen,Dietlinde Janson,Mirjam Korporal-Kuhnke,Markus Kowarik,Nikolaus Kröger,Jan D Lünemann,Roland Martin,Uwe Meier,Sven Meuth,Paolo Muraro,Michael Platten,Lucas Schirmer,Klarissa Hanja Stürner,Jan Patrick Stellmann,Christof Scheid,Florian Then Bergh
Background While substantial progress has been made in the development of disease-modifying medications for multiple sclerosis (MS), a high percentage of treated patients still show progression and persistent inflammatory activity. Autologous haematopoietic stem cell transplantation (AHSCT) aims at eliminating a pathogenic immune repertoire through intense short-term immunosuppression that enables
-
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-09-26 Richard Nicholas,Jeff Rodgers,James Witts,Annalaura Lerede,Tim Friede,Jan Hillert,Lars Forsberg,Anna Glaser,Ali Manouchehrinia,Ryan Ramanujam,Tim Spelman,Pernilla Klyve,Jiri Drahota,Dana Horakova,Hanna Joensen,Luigi Pontieri,Melinda Magyari,David Ellenberger,Alexander Stahmann,Helmut Butzkueven,Anneke Van Der Walt,Vladimir Bezlyak,Carol Lines,Rod Middleton
Introduction Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing-remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising the approach to diagnosis of disease course, for example, assigning RRMS or secondary progressive MS (SPMS) diagnoses, allows examination of the impact of
-
A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-09-21 Clara Grazia Chisari,Joe Guadagno,Peyman Adjamian,Carlos Vila Silvan,Teresa Greco,Makarand Bagul,Francesco Patti
Background Over 80% of individuals with multiple sclerosis (MS) experience MS-associated spasticity (MSS). In many European countries, after failure of first-line treatments, moderate or severe MSS can be treated with nabiximols, a cannabis-based add-on treatment. Objective This post hoc analysis assessed the shift of participants treated with nabiximols from higher (severe or moderate) to lower (moderate
-
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-09-21 Alasdair J Coles,Anat Achiron,Anthony Traboulsee,Barry A Singer,Carlo Pozzilli,Celia Oreja-Guevara,Gavin Giovannoni,Giancarlo Comi,Mark S Freedman,Tjalf Ziemssen,Debora Shiota,Andreea M Rawlings,Alana T Wong,Magdalena Chirieac,Xavier Montalban
Background and objectives Alemtuzumab demonstrated superior efficacy versus subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple sclerosis in the 2-year CARE-MS I and II trials. Efficacy was maintained in the 4-year CARE-MS extension, during which alemtuzumab-treated participants ('alemtuzumab-only') could receive additional courses upon disease activity, and IFN-treated
-
Recent progress in epidemiology, clinical features, and therapy of multiple sclerosis in China. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-09-15 Meng Wang,Caiyun Liu,Meijuan Zou,Zixuan Niu,Jie Zhu,Tao Jin
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system characterized by inflammation, demyelination, and neurodegeneration. It mainly affects young adults, imposing a heavy burden on families and society. The epidemiology, clinical features, and management of MS are distinct among different countries. Although MS is a rare disease in China, there are 1.4 billion people in
-
A 20-year multicentre retrospective review of optic nerve sheath fenestration outcomes. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-09-13 Shaddy El-Masri,Matthew Wilson,Jonathan Goh,Paul Sanfilippo,Anthony Fok,Thomas Hardy,Rahul Chakrabarti,Anneke Van Der Walt
Background Optic nerve sheath fenestration (ONSF) longitudinal outcomes remain unclear and are vital in the assessment of vision failure in patients with raised intracranial pressure (ICP). Furthermore, limited observational data exists regarding its use in other causes of raised ICP. Objective To determine the efficacy and safety of ONSF for idiopathic intracranial hypertension (IIH), cerebral venous
-
Factors associated with depressive mood at the onset of multiple sclerosis - an analysis of 781 patients of the German NationMS cohort. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-09-08 Anke Salmen,Robert Hoepner,Vinzenz Fleischer,Milena Heldt,Barbara Gisevius,Jeremias Motte,Klemens Ruprecht,Ruth Schneider,Anna Lena Fisse,Thomas Grüter,Carsten Lukas,Achim Berthele,Katrin Giglhuber,Martina Flaskamp,Mark Mühlau,Jan Kirschke,Stefan Bittner,Sergiu Groppa,Felix Lüssi,Antonios Bayas,Sven Meuth,Cristoph Heesen,Corinna Trebst,Brigitte Wildemann,Florian Then Bergh,Gisela Antony,Tania Kümpfel
Background Depression has a major impact on the disease burden of multiple sclerosis (MS). Analyses of overlapping MS and depression risk factors [smoking, vitamin D (25-OH-VD) and Epstein-Barr virus (EBV) infection] and sex, age, disease characteristics and neuroimaging features associated with depressive symptoms in early MS are scarce. Objectives To assess an association of MS risk factors with
-
Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: post hoc analysis of a phase III trial and open-label extension study. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-09-04 Eugen Trinka,Rodrigo Rocamora,João Chaves,Mathias J Koepp,Stephan Rüegg,Martin Holtkamp,Joana Moreira,Miguel M Fonseca,Guillermo Castilla-Fernández,Fábio Ikedo
Background Antiseizure medications can have negative effects on plasma lipid levels. Objectives To evaluate plasma lipid changes in patients with newly diagnosed focal epilepsy treated with eslicarbazepine acetate (ESL) or controlled-release carbamazepine (CBZ-CR) monotherapy during a phase III, randomized, double-blind (DB) trial and 2 years of ESL treatment in an open-label extension (OLE). Design
-
Objectivity, practicality, and significance of practice guidelines for the practicing neurologists: What we learnt from consensus criteria in CIDP, Myasthenia Gravis and Inflammatory Myopathies. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-09-04 Marinos C Dalakas
The value of practice guidelines in the three most common autoimmune neuromuscular disorders, namely Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Myasthenia Gravis (MG) and Autoimmune Inflammatory Myopathies (AIM), has been extensively debated regarding their usefulness in clinical practice, objectivity and universal value considering that guidelines are also established regionally in
-
Prevalence and risk factors of anxiety and depression in adult patients with epilepsy: a multicenter survey-based study. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-08-30 Wenyan Shi,Hanlin Sun,Wei Peng,Ziyi Chen,Qun Wang,Weihong Lin,Meiping Ding,Hongbin Sun,Xiangqing Wang,Tiancheng Wang,Xuefeng Wang,Yonghong Liu,Yangmei Chen,Guoxing Zhu,Dong Zhou,Jinmei Li
Background Depression and anxiety are the most common psychiatric comorbidities in patients with epilepsy (PWE). However, they are often unrecognized and consequently untreated. Objective The study was conducted to evaluate the prevalence and risk factors of anxiety and depression among Chinese adult PWE. Design Cross-sectional study. Methods Adult PWE were recruited from 13 tertiary epilepsy centers
-
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-08-30 Graeme J Sills
Developmental and epileptic encephalopathies (DEEs) are rare neurodevelopmental disorders characterised by early-onset and often intractable seizures and developmental delay/regression, and include Dravet syndrome and Lennox-Gastaut syndrome (LGS). Rufinamide, fenfluramine, stiripentol, cannabidiol and ganaxolone are antiseizure medications (ASMs) with diverse mechanisms of action that have been approved
-
Impact of the updated chronic inflammatory demyelinating polyneuropathy guideline on everyday clinical practice. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-08-24 Suraj Muley,Said R Beydoun
-
A narrative review and expert recommendations on the assessment of the clinical manifestations, follow-up, and management of post-OLT patients with ATTRv amyloidosis. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-08-24 Carlos Casasnovas,Laura Lladó,Cristina Borrachero,Patricia Valentina Pérez-Santamaría,Francisco Muñoz-Beamud,Inés Asunción Losada-López,Maria Carme Baliellas-Comellas,Juan González-Moreno
Orthotopic liver transplantation (OLT) was the first treatment able to modify the natural course of hereditary transthyretin (ATTRv) amyloidosis, which is a rare and fatal disorder caused by the accumulation of misfolded transthyretin (TTR) variants in different organs and tissues and which leads to a progressive and multisystem dysfunction. Because the liver is the main source of TTR, OLT dramatically
-
IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-08-17 Isabel Sánchez-Vera,Esther Escudero,Úrsula Muñoz,María C Sádaba
Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease of the central nervous system. It affects young people, and a considerable percentage of patients need the help of a wheelchair in 15 years of evolution. Currently, there is not a specific technique for the diagnosis of MS. The detection of oligoclonal IgG bands (OIgGBs) is the most sensitive assay for it, but it is not standardizable
-
Contactin-associated protein 2 autoantibodies can be associated with multifocal motor-like neuropathy: a case report. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-08-16 Louisa Müller-Miny,Raoul Sauer,Andreas Schulte-Mecklenbeck,Catharina C Gross,Stjepana Kovac,Matthias Schilling,Carolin Beuker,Heinz Wiendl,Gerd Meyer Zu Hörste
Autoantibodies against contactin-associated protein 2 (CASPR2) are usually associated with autoimmune encephalitis and neuromyotonia. Their association with inflammatory neuropathies has been described in case reports albeit all with distal symmetric manifestation. Here, we report a patient who developed distal arm paresis, dominantly of the right arm, over the course of 1 year. Electroneurography
-
mTOR pathway - a potential therapeutic target in stroke. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-08-09 Konstantinos Melanis,Maria-Ioanna Stefanou,Konstantinos M Themistoklis,Themistoklis Papasilekas
Stroke is ranked as the second leading cause of death worldwide and a major cause of long-term disability. A potential therapeutic target that could offer favorable outcomes in stroke is the mammalian target of rapamycin (mTOR) pathway. mTOR is a serine/threonine kinase that composes two protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), and is regulated by other proteins such
-
The effectiveness of teriflunomide in patients with multiple sclerosis in China: a real-world comparison to no DMT treatment in the first year after diagnosis. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-07-24 Bitao Bu,Chao Quan,Wenyu Li,Qiuming Zeng,Ziyan Shi,Bo Chen,Lei Zhou,Luya Jin,Hongyu Zhou,Huan Yang
Background Teriflunomide is a first-line oral immunomodulatory agent approved in China for the treatment of relapsing multiple sclerosis. Objective To compare the treatment outcomes of teriflunomide and no disease-modifying therapy (DMT) treatment (in first year) in multi-center real-world Chinese multiple sclerosis patients. Design Retrospective study. Methods This study was conducted in five tertiary
-
Therapeutic plasma exchange in the management of stiff person syndrome spectrum disorders: a case series and review of the literature. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-07-24 Nicolas Mercure-Corriveau,Shuvro Roy,Chen Hu,Elizabeth P Crowe,Xianming Zhu,Danielle Obando,Eshan U Patel,Aaron A R Tobian,Yujie Wang,Evan M Bloch,Scott D Newsome
Background Stiff person syndrome spectrum disorders (SPSD) are a rare group of disabling neuroimmunological disorders. SPSD often requires immune therapies, especially in the setting of inadequate response to symptomatic treatments. The safety and efficacy of therapeutic plasma exchange (TPE) in SPSD remains uncertain. Objectives To describe the safety, tolerability, and efficacy of TPE in patients
-
Complete remission of central nervous system manifestations of IgG4-related disease with rituximab - a case report. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-07-18 Aleksi J Sihvonen,Sini M Laakso,Olli Tynninen,Heikki Saaren-Seppälä,Mervi Löfberg
IgG4-related disease (IgG4-RD) is an emerging immune-mediated chronic fibrotic disease characterized by tumour-like mass formation. Reports of brain parenchymal involvement in IgG4-RD are rare and complete treatment-related remission of lesions has never been reported. Here, we present a woman in her mid-50s who developed headache and seizures. Brain magnetic resonance imaging revealed frontal bilateral
-
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-07-14 Ralf Gold,Michael Barnett,Andrew Chan,Huiyu Feng,Kazuo Fujihara,Gavin Giovannoni,Xavier Montalbán,Fu-Dong Shi,Mar Tintoré,Qun Xue,Chunsheng Yang,Hongyu Zhou
Dimethyl fumarate (DMF) is a widely used oral disease-modifying therapy for multiple sclerosis (MS). Its efficacy and safety profiles are supported by over a decade of experience. Differences exist between Asia and Europe/United States in the prevalence and characteristics of MS; most data for DMF are derived from populations outside Asia. DMF was recently (2021) approved for use in China. The objectives
-
Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-07-08 Diego Centonze,Maria Pia Amato,Vincenzo Brescia Morra,Eleonora Cocco,Nicola De Stefano,Claudio Gasperini,Paolo Gallo,Carlo Pozzilli,Maria Trojano,Massimo Filippi
Multiple sclerosis (MS) is a chronic, progressive neurological disease involving neuroinflammation, neurodegeneration, and demyelination. Cladribine tablets are approved for immune reconstitution therapy in patients with highly active relapsing-remitting MS based on favorable efficacy and tolerability results from the CLARITY study that have been confirmed in long-term extension studies. The approved
-
Cardiac therapies for Duchenne muscular dystrophy. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-07-03 Md Nur Ahad Shah,Toshifumi Yokota
Duchenne muscular dystrophy (DMD) is a devastating disease that results in life-limiting complications such as loss of skeletal muscle function as well as respiratory and cardiac complications. Advanced therapeutics in pulmonary care have significantly reduced respiratory complication-related mortality, making cardiomyopathy the main determinant factor of survival. While there are multiple therapies
-
Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-06-30 Ichiro Nakashima,Jin Nakahara,Hiroaki Yokote,Yasuhiro Manabe,Kazumi Okamura,Kou Hasegawa,Kazuo Fujihara
Background The terminal complement C5 inhibitor eculizumab is approved in Japan for relapse prevention in aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) and is undergoing mandatory post-marketing surveillance (PMS) of clinical use. Objectives The objective of the study is to assess the real-world, long-term safety and effectiveness of eculizumab in Japanese patients
-
Is the central nervous system enclosed by a mesothel? Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-06-26 Karl Hartmann,Belal Neyazi,Klaus-Peter Stein,Aiden Haghikia,I Erol Sandalcioglu
-
Comparative efficacy and safety of various mechanical thrombectomy strategies for patients with acute ischemic stroke: a Bayesian network meta-analysis. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-06-25 Jiahao Meng,Zeya Yan,Jie Zhang,Wei Wang,Xinyu Tao,Feng Gu,Xingyu Yang,Tao Xue,Wanchun You,Zhouqing Chen,Zhong Wang,Gang Chen
Background Stent retriever, contact aspiration, and combined treatment are crucial mechanical thrombectomy strategies for patients with acute ischemic stroke (AIS). Objectives The aim of this study was to compare and rank three different mechanical thrombectomy strategies for AIS due to large vessel occlusion by means of a Bayesian network meta-analysis. Design A systematic review and Bayesian network
-
Attenuation of immune activation in patients with multiple sclerosis on a wheat-reduced diet: a pilot crossover trial. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-06-25 Sinah Engel,Luisa Klotz,Timo Wirth,Ann-Katrin Fleck,Geethanjali Pickert,Melanie Eschborn,Samia Kreuzburg,Valentina Curella,Stefan Bittner,Frauke Zipp,Detlef Schuppan,Felix Luessi
Background Western lifestyle has been associated with an increase in relapsing-remitting multiple sclerosis (RRMS). In mice, dietary wheat amylase-trypsin inhibitors (ATIs) activate intestinal myeloid cells and augment T cell-mediated systemic inflammation. Objective The aim of this study was to assess whether a wheat- and thus ATI-reduced diet might exert beneficial effects in RRMS patients with modest
-
Lexical and syntactic deficits analyzed via automated natural language processing: the new monitoring tool in multiple sclerosis. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-06-25 Martin Šubert,Michal Novotný,Tereza Tykalová,Barbora Srpová,Lucie Friedová,Tomáš Uher,Dana Horáková,Jan Rusz
Background Impairment of higher language functions associated with natural spontaneous speech in multiple sclerosis (MS) remains underexplored. Objectives We presented a fully automated method for discriminating MS patients from healthy controls based on lexical and syntactic linguistic features. Methods We enrolled 120 MS individuals with Expanded Disability Status Scale ranging from 1 to 6.5 and
-
Magnetic Resonance-guided Focused Ultrasound thalamotomy for refractory neuropathic pain: a systematic review and critical appraisal of current knowledge. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-06-19 Valentina Taranta,Gennaro Saporito,Raffaele Ornello,Alessandra Splendiani,Federico Bruno,Patrizia Sucapane,Carlo Masciocchi,Franco Marinangeli,Angelo Cacchio,Ernesto Di Cesare,Francesca Pistoia
Background Magnetic Resonance-guided Focused Ultrasound (MRgFUS) is an innovative therapeutical approach for medically refractory tremor. It is currently under investigation for other neurological diseases including refractory neuropathic pain (NP). Objective The objective of this systematic review is to analyze available evidence about the effectiveness and safety profile of MRgFUS in the treatment
-
Acute reperfusion treatment and secondary prevention of cancer-related stroke: comprehensive overview and proposal of clinical algorithm. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-06-16 Athina-Maria Aloizou,Lina Palaiodimou,Dimitra Aloizou,Efthimios Dardiotis,Ralf Gold,Georgios Tsivgoulis,Christos Krogias
Cancer-related stroke (CRS), referring to ischemic stroke occurring in cancer patients without other clear etiology, represents a clinical challenge, as it is associated with unfavorable clinical outcomes including high rates of recurrence and mortality. There are scarce international recommendations and limited consensus statements on CRS management. For this comprehensive overview, the available
-
Arterial stiffness and its influence on cerebral morphology and cognitive function. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-06-15 Melanie Haidegger,Simon Lindenbeck,Edith Hofer,Christina Rodler,Robert Zweiker,Sabine Perl,Lukas Pirpamer,Markus Kneihsl,Simon Fandler-Höfler,Thomas Gattringer,Christian Enzinger,Reinhold Schmidt
Background Recently, arterial stiffness has been associated with cerebral small vessel disease (SVD), brain atrophy and vascular dementia. Arterial stiffness is assessed via pulse wave velocity (PWV) measurement and is strongly dependent on arterial blood pressure. While circadian blood pressure fluctuations are important determinants of end-organ damage, the role of 24-h PWV variability is yet unclear
-
Autonomic dysfunction entwined with post-COVID but absent in non-post-COVID patients: a neurophysiological and neurosonology study. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-06-15 Marianna Papadopoulou,Eleni Bakola,Apostolos Papapostolou,Maria-Ioanna Stefanou,Elisabeth Andreadou,Vasiliki Zouvelou,Maria Stefanatou,Mina Gaga,Ioannis Michopoulos,Georgios Tsivgoulis
-
Flow diversion for posterior circulation aneurysms: a multicenter retrospective study. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-06-08 Peng Qi,Xin Tong,Xin Liang,Xiaopeng Xue,Zhongxue Wu,Xin Feng,Meng Zhang,Zhiqun Jiang,Daming Wang,Aihua Liu
Background The prevalence of intracranial aneurysms is approximately 3% worldwide. Posterior circulation (PC) aneurysms have a higher risk of treatment complications than anterior circulation aneurysms. Improving the survival rate and quality of life of patients with PC aneurysms remains one of the most important issues in the field. Objectives Flow diverter (FD) treatment of PC aneurysms remains controversial
-
Acceptance, drivers, and barriers to use eHealth interventions in patients with post-COVID-19 syndrome for management of post-COVID-19 symptoms: a cross-sectional study. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-05-27 Julia Schröder,Alexander Bäuerle,Lisa Maria Jahre,Eva-Maria Skoda,Mark Stettner,Christoph Kleinschnitz,Martin Teufel,Hannah Dinse
Background Post-COVID-19 syndrome is a new and debilitating disease without adequate treatment options. eHealth could be a reasonable approach for symptom management. Objectives This study aims to evaluate the acceptance for eHealth interventions for symptom management in individuals with post-COVID-19 syndrome, as well as drivers and barriers influencing acceptance. Design Cross-sectional study. Methods
-
Impact of prehospital stroke triage implementation on patients with intracerebral hemorrhage Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-05-10 Tove Almqvist, Anna Falk Delgado, Christina Sjöstrand, Niaz Ahmed, Annika Berglund, Einar Eriksson, Michael V. Mazya
Background:Little is known about how prehospital triage using large vessel occlusion (LVO) stroke prediction scales affects patients with intracerebral hemorrhage (ICH).Objectives:We aimed to inves...
-
Sleep outcomes and related factors in Parkinson’s disease after subthalamic deep brain electrode implantation: a retrospective cohort study Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-05-10 Ruoyu Ma, Zixiao Yin, Yingchuan Chen, Tianshuo Yuan, Qi An, Yifei Gan, Yichen Xu, Yin Jiang, Tingting Du, Anchao Yang, Fangang Meng, Guanyu Zhu, Jianguo Zhang
Background:Subthalamic nucleus deep brain stimulation (STN-DBS) improves sleep qualities in Parkinson’s disease (PD) patients; however, it remains elusive whether STN-DBS improves sleep by directly...
-
Could statin improve outcomes after pipeline embolization for intracranial aneurysms in a real-world setting? Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-05-10 Xinrui Wang, Mirzat Turhon, Xinjian Yang, Jianmin Liu, Hongqi Zhang, Tianxiao Li, Donglei Song, Yuanli Zhao, Sheng Guan, Aisha Maimaitili, Yunyan Wang, Wenfeng Feng, Jieqing Wan, Guohua Mao, Huaizhang Shi, Zhuoling An, Yang Wang
Background:Several pharmacological pathways have revealed statin to have a positive role in patients with for intracranial aneurysms. However, prior studies regarding the association between statin...
-
Comment on 'The overlapping relationship among depression, anxiety, and somatic symptom disorder and its impact on the quality of life of people with epilepsy'. Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-04-27 Agata M Grzegorzewska,Mariusz S Wiglusz,Wiesław J Cubała
-
The severity of corneal nerve loss differentiates motor subtypes in patients with Parkinson’s disease Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-04-19 Ning-Ning Che, Qiu-Huan Jiang, Shuai Chen, Si-Yuan Chen, Zhen-Xiang Zhao, Xue Li, Jian-Jun Ma, Jie-Wen Zhang, Rayaz A. Malik, Hong-Qi Yang
Background:Parkinson’s disease (PD) is a heterogeneous movement disorder with patients manifesting with either tremor-dominant (TD) or postural instability and gait disturbance (PIGD) motor subtype...
-
Endovascular treatment of acute basilar artery occlusion in patients with and without atrial fibrillation: results from the ATTENTION registry Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-04-19 Shuo Feng, Tong Li, Yingchun Wu, Hongchao Shi, Yongchang Liu, Bo Xu, Chenghua Xu, Qingqing Zhou, Fengling Qu, Rui Li, Chunrong Tao, Wen Sun, Wei Hu, Xinfeng Liu
Background:Previous studies have shown a potential beneficial effect of endovascular therapy (EVT) in patients with acute basilar artery occlusion (BAO). It was unclear that whether atrial fibrilla...
-
The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-04-17 Ana Klein, Martina Flaskamp, Achim Berthele, Friederike Held, Harisa Muratovic, Bernhard Hemmer
Background:Although disease-modifying therapies (DMTs) in multiple sclerosis (MS) are known to target the immune system, mechanisms of action, efficacy, safety, and tolerability profiles differ. Th...
-
Clinical and electrophysiological characteristics of peripheral neuropathy in autoimmune glial fibrillary acidic protein astrocytopathy: an observational study and literature review Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-04-07 Bo Deng, Jingguo Wang, Yue Qiu, Xiaoni Liu, Lei Jin, Dongqing Zhu, Xiangjun Chen
Background:The phenotype of peripheral neuropathy (PN) associated with glial fibrillary acidic protein-immunoglobulin G (GFAP-IgG) has not been well described.Objectives:The aim of this study was t...
-
Immunotherapy for ocular myasthenia gravis: an observational study in Japan Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-04-04 Tomoko Narita, Shunya Nakane, Akiko Nagaishi, Naoya Minami, Masaaki Niino, Naoki Kawaguchi, Hiroyuki Murai, Jun-ichi Kira, Jun Shimizu, Kazuo Iwasa, Hiroaki Yoshikawa, Yuki Hatanaka, Masahiro Sonoo, Yuko Shimizu, Hidenori Matsuo
Background:Treatment for ocular myasthenia gravis (OMG) has not yet been well established. Few reports have been published on the clinical practice and outcomes of OMG.Objectives:We investigated tr...
-
Locked-in syndrome revisited Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-03-29 Laura Schnetzer, Mark McCoy, Jürgen Bergmann, Alexander Kunz, Stefan Leis, Eugen Trinka
The locked-in syndrome (LiS) is characterized by quadriplegia with preserved vertical eye and eyelid movements and retained cognitive abilities. Subcategorization, aetiologies and the anatomical fo...
-
Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-03-29 Ashwin A. Pinto, Jerome De Seze, Anu Jacob, Stephen Reddel, Anna Yudina, Kevin Tan
Background:Intravenous immunoglobulin (IVIg) and therapeutic plasma exchange (TPE) are among the main immunotherapies for neurological disorders. Their benefit is greatest in immune-mediated condit...
-
A novel use and dramatic efficacy of ofatumumab for the treatment of anti-N-methyl-D-aspartate receptor encephalitis: a report of two cases Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-03-25 Xue Gong, Dong Zhou, Zhen Hong
Ofatumumab (OFA), a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B-cells. The purpose of this study was to report the therapeutic effect and safety of OFA in two refractory anti...
-
International beliefs and head positioning practices in patients with spontaneous hyperacute intracerebral hemorrhage Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-03-24 Wendy Dusenbury, Marc D. Malkoff, Peter D. Schellinger, Martin Köhrmann, Adam S. Arthur, Lucas Elijovich, Andrei V. Alexandrov, Georgios Tsivgoulis, Anne W. Alexandrov
Background:Prior to the conduct of the Head Position in Stroke Trial (HeadPoST), an international survey (n = 128) revealed equipoise for selection of head position in acute ischemic stroke.Objecti...
-
PGC1α: an emerging therapeutic target for chemotherapy-induced peripheral neuropathy Ther. Adv. Neurol. Disord. (IF 5.9) Pub Date : 2023-03-25 Mingzhu Zhai, Haibei Hu, Yi Zheng, Benqing Wu, Wuping Sun
Chemotherapy-induced peripheral neuropathy (CIPN)-mediated paresthesias are a common complication in cancer patients undergoing chemotherapy. There are currently no treatments available to prevent ...